ABO and Alzheimer disease: Several biomarkers of the essential role of PrPC in neuronal AD phenotypes are translatable to clinical scenarios, including SV2A PET [27] and pThr217 levels [51], and these may be used to assess the therapeutic efficacy of targeting Aβo-PrPC interaction in AD.